Podcast Episodes
Back to Search
Ep. 386 - Novartis misses, pharma deals analysis, MFN carve-outs
Season 7 Episode 386
Novartis' pelacarsen Phase III miss has wiped more than $40 billion in market cap and raised questions about whether the problem is target biology, …
7 hours ago
Ep. 385 - MFN deals, Lilly takeout, FDA pick Overton
Season 7 Episode 385
Mid-sized biopharma companies are under growing pressure to accept most-favored nation drug pricing deals with the White House. On the latest BioCent…
1 week, 1 day ago
Ep. 384 - Back to School Special: The global FIH trials race
China has changed the global narrative on delivering early human clinical data, with a new bar for speed and efficiency. And now drug developers and …
1 week, 5 days ago
Ep. 383 - Moderna, Genentech obesity deal, Trump's FDA pick
Season 7 Episode 383
A Phase III win for a melanoma vaccine from Moderna and Merck & Co. has opened the door to personalized neoantigen vaccines. On the latest BioCentury…
2 weeks, 1 day ago
Ep. 382 - Summer’s venture wave; drugging beta-catenin; Capricor & FDA
Season 7 Episode 382
A baker’s dozen of biotechs shrugged off the summer haze to raise nearly $800 million in venture cash. On the latest BioCentury This Week podcast, Bi…
3 weeks, 1 day ago
Ep. 381 - FIH urgency in the U.S. Plus: federated learning, biotech IPOs
Season 7 Episode 381
Pressure is on FDA, policymakers and academic centers in the U.S. to respond to challenges from China, Australia, and beyond to run first in human tr…
4 weeks, 1 day ago
Ep. 380 - AZ-BMS rumors, Replimune, psychedelics
Season 7 Episode 380
Rumors flew this weekend about a mega-merger of AstraZeneca and Bristol Myers — but would such a deal make sense? On the latest BioCentury This Week …
1 month ago
Ep. 379 - Argenx M&A, AI giants and biopharma, catalyst scorecard
Season 7 Episode 379
Argenx the tier-jumping European biotech, believes its proposed $2.2 billion purchase of Forte Biosciences will add a second multi-indication product…
1 month, 1 week ago
Ep. 378 - U.K. cabinet shuffle, Taiwan biotech and Biogen data
The departure of U.K. Science Minister Patrick Vallance is a blow for U.K. biotech. On the latest BioCentury This Week podcast, BioCentury’s analysts…
1 month, 2 weeks ago
Ep. 377 - Trends in life sciences talent with CBRE's Ian Anderson
Season 7 Episode 377
After nearly three years of sluggish job growth, hiring is turning a corner in the U.S. life sciences industry, while the talent pool is expanding be…
1 month, 3 weeks ago